Claire E Wainwright
Overview
Explore the profile of Claire E Wainwright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
3371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomson R, Wheeler N, Stockwell R, Bryant J, Taylor S, Leong L, et al.
Am J Respir Crit Care Med
. 2025 Mar;
PMID: 40072241
Rationale: group bacteria (MABS) cause lethal infections in people with chronic lung diseases. Transmission mechanisms remain poorly understood; the detection of dominant circulating clones (DCCs) has suggested potential for person-to-person...
2.
ODonnell J, Hastings L, Briody J, Chan C, Colombo C, Douglas T, et al.
Pediatr Pulmonol
. 2025 Feb;
59(6):1661-1676.
PMID: 39903130
Background: Cystic fibrosis (CF) is a life-shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF-related lung disease, with...
3.
Tay G, Smith K, He C, Ballard E, Wood M, Stockwell R, et al.
J Cyst Fibros
. 2025 Jan;
PMID: 39884883
Background: People with cystic fibrosis (CF) are recommended to wear face-masks when in healthcare settings. We previously demonstrated that face-masks significantly reduce the release of Pseudomonas aeruginosa (P. aeruginosa) aerosols...
4.
Douglas T, Deery M, Kimball H, Cobham V, Panochini S, Robinson P, et al.
J Cyst Fibros
. 2024 Nov;
PMID: 39490214
No abstract available.
5.
Jain K, Wainwright C, Smyth A
Cochrane Database Syst Rev
. 2024 May;
5:CD009530.
PMID: 38700027
Background: Early diagnosis and treatment of lower respiratory tract infections is the mainstay of management of lung disease in cystic fibrosis (CF). When sputum samples are unavailable, diagnosis relies mainly...
6.
Blake T, Sly P, Andersen I, Wainwright C, Reid D, Bell S, et al.
J Cyst Fibros
. 2024 Apr;
23(6):1163-1166.
PMID: 38658253
There is an urgent need to develop sensitive, non-invasive biomarkers that can track airway inflammatory activity for patients with cystic fibrosis (CF). Urinary glutathione sulfonamide (GSA) levels correlate well with...
7.
Tarique A, Tuladhar N, Kelk D, Begum N, Lucas R, Luo L, et al.
Cells
. 2024 Jan;
13(2).
PMID: 38247856
Background: Azithromycin (AZM) is widely being used for treating patients with cystic fibrosis (pwCF) following clinical trials demonstrating improved lung function and fewer incidents of pulmonary exacerba-tions. While the precise...
8.
Hisert K, Birket S, Clancy J, Downey D, Engelhardt J, Fajac I, et al.
Lancet Respir Med
. 2023 Sep;
11(10):916-931.
PMID: 37699420
Cystic fibrosis is a multiorgan disease caused by impaired function of the cystic fibrosis transmembrane conductance regulator (CFTR). Since the introduction of the CFTR modulator combination elexacaftor-tezacaftor-ivacaftor (ETI), which acts...
9.
Robinson P, Douglas T, Wainwright C
Lancet Respir Med
. 2023 Jun;
11(9):e78.
PMID: 37321239
No abstract available.
10.